Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARATSE:MOZ Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.87+19.2%$0.73$0.50▼$5.20$39.91M0.7748,054 shs569,125 shsMOZMarathon GoldC$0.77C$0.49▼C$1.08C$380.02M1.68737,767 shs974,784 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+19.01%-3.74%+8.48%+13.27%-82.41%MOZMarathon Gold0.00%0.00%0.00%-2.41%-8.99%Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics4.4374 of 5 stars3.42.00.04.23.81.71.3MOZMarathon GoldN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,021.98% UpsideMOZMarathon Gold2.60Moderate BuyC$0.99∞ UpsideCurrent Analyst RatingsLatest MOZ, CARA, GLOO, XAF, and TNI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/22/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.001/12/2024MOZMarathon GoldRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetC$0.75 ➝ C$0.80(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M2.27N/AN/A$1.05 per share0.83MOZMarathon GoldN/AN/AN/A2.17C$0.92 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)MOZMarathon Gold-C$18.24M-C$0.05N/AN/AN/AN/A-4.93%-1.59%N/ALatest MOZ, CARA, GLOO, XAF, and TNI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AMOZMarathon GoldN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43MOZMarathon Gold96.921.688.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%MOZMarathon Gold36.33%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%MOZMarathon Gold14.66%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableMOZMarathon Gold634469.16 millionN/ANot OptionableMOZ, CARA, GLOO, XAF, and TNI HeadlinesSourceHeadlineMarathon Gold Co. (TSE:MOZ) Given Average Recommendation of "Moderate Buy" by Brokeragesamericanbankingnews.com - March 18 at 4:32 AMHilight Zone Podcast: Aiming to be Gold Ball Worthywsaw.com - March 14 at 1:44 AMPRECIOUS-Gold's record run stalls ahead of US inflation printmsn.com - March 13 at 8:51 AMGold's record run continuesmsn.com - March 12 at 5:12 PM2024 Kentucky Derby Festival marathon and miniMarathon finisher medals unveiledmsn.com - March 7 at 10:02 PMIs Tokyo Marathon on TV? Start time and how to watch as Eliud Kipchoge returnsaol.com - March 3 at 5:19 PMTokyo Marathon 2024: Eliud Kipchoge’s Glorious Career Takes a Hit With Lowest Career Finishmsn.com - March 3 at 1:48 AMUS Olympic Marathon Trials: The “Never Give Up” Journey of Dakotah Lindwurm Unwrappedmsn.com - February 9 at 1:49 PMWill the US Olympic marathon team run through Utah?ksl.com - February 3 at 8:28 AMMarathon Gold:Stocks Analysts Recently Upgraded on TSX (MOZ)theglobeandmail.com - January 30 at 7:39 PMMarathon Gold Corporation: Marathon Gold Announces Receipt of Final Court Order for Arrangement with Calibre Miningfinanznachrichten.de - January 23 at 7:25 AMIndependent Proxy Advisory Firms, ISS and Glass Lewis, Recommend Marathon Shareholders Vote FOR ...bakersfield.com - January 9 at 9:57 AMIndependent Proxy Advisory Firms, ISS and Glass Lewis, Recommend Marathon Shareholders Vote FOR the Arrangement with Calibrefinance.yahoo.com - January 9 at 9:57 AMIndependent Proxy Advisory Firms, ISS and Glass Lewis, Recommend Marathon Shareholders Vote FOR the Arrangement with Calibrefinance.yahoo.com - January 9 at 9:57 AMMOZ:CA Marathon Gold Corporationseekingalpha.com - January 5 at 4:52 PMKipchoge tips Cheptegei to break marathon recordmsn.com - December 1 at 7:43 AMRunners of miniMarathon, Marathon to receive rose medals in honor of 150th Kentucky Derbymsn.com - November 14 at 8:17 PMCalibre and Marathon Announce Combination to Create a High-Growth, Cash Flow Focused ...goldseiten.de - November 13 at 8:19 AMFind Your Finish: Watch the 2023 TCS New York City Marathon finish line here!abc7ny.com - November 6 at 3:40 PMSmashed records bring new focus to marathon ahead of New Yorkreuters.com - November 2 at 3:47 PMMarathon Gold shares rise as its proposed Berry pit expansion passes provincial EA processmining.com - October 30 at 5:36 PMMarathon Gold Confirms Valentine Gold Project Berry Expansion Released from Provincial Environmental Assessment Processfinance.yahoo.com - October 30 at 7:35 AMNYC Marathon: Olympic, world record and marathon legends coming to Staten Island once againsilive.com - October 24 at 10:22 AMMarathon Gold Provides Third Quarter 2023 Construction Reportfinance.yahoo.com - October 23 at 7:54 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Marathon GoldTSE:MOZMarathon Gold Corporation acquires, explores for, and develops mineral resource projects in Canada. The company explores for gold, and precious and base metal deposits. Its flagship property is the Valentine Lake gold property with five mineralized deposits located in Central Region of Newfoundland and Labrador, Canada. The company was incorporated in 2009 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.